Lyell Immunopharma, Inc. Common Stock (LYEL) is a publicly traded Healthcare sector company. As of September 10, 2026, LYEL trades at $12.19 with a market cap of $315.63M and a P/E ratio of -0.95. LYEL moved -4.27% today. Year to date, LYEL is -57.90%; over the trailing twelve months it is -6.66%. Its 52-week range spans $7.65 to $45.00. Analyst consensus is buy with an average price target of $36.20. Rallies surfaces LYEL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies AI research for LYEL combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
| Metric | Value |
|---|---|
| Price | $12.19 |
| Market Cap | $315.63M |
| P/E Ratio | -0.95 |
| EPS | $-12.83 |
| Dividend Yield | 0.00% |
| 52-Week High | $45.00 |
| 52-Week Low | $7.65 |
| Volume | 101.83K |
| Avg Volume | 0 |
| Revenue (TTM) | $27.00K |
| Net Income | $-248.48M |
| Gross Margin | 0.00% |
5 analysts cover LYEL: 0 strong buy, 4 buy, 0 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $36.20.